Gateva Antoaneta, Unfer Vittorio, Kamenov Zdravko
a Clinic of Endocrinology , Alexandrovska University Hospital, Medical University , Sofia , Bulgaria.
b Health Department , UniPoliSi - Institut des Etudes Universitaires , Disentis , Switzerland.
Gynecol Endocrinol. 2018 Jul;34(7):545-550. doi: 10.1080/09513590.2017.1421632. Epub 2018 Jan 8.
The aim of this review is to present the current data about the role of inositols in the management of polycystic ovary syndrome (PCOS) women and in the prevention and treatment of gestational diabetes mellitus (GDM). We analyzed the available literature with key words PCOS, Myo-inositol, D-chiro-inositol, assisted reproductive technologies and GDM. The most recent literature would suggest that Myo-inositol, D-chiro-inositol and their combination in physiological ratio 40:1 could represent an important therapeutic strategy for the improvement of metabolic, hormonal and reproductive aspects of PCOS. In assisted reproductive technologies, however, myo-inositol and the combined treatment, despite D-chiro-inositol monotherapy, are able to improve clinical outcomes. Myo-inositol monotherapy results more effective in preventing and treating GDM even if a larger cohort of studies is needed to better clarify these results.
本综述的目的是介绍有关肌醇在多囊卵巢综合征（PCOS）女性管理以及妊娠糖尿病（GDM）预防和治疗中作用的当前数据。我们用关键词PCOS、肌醇、D-手性肌醇、辅助生殖技术和GDM分析了现有文献。最新文献表明，肌醇、D-手性肌醇及其40:1的生理比例组合可能是改善PCOS代谢、激素和生殖方面的重要治疗策略。然而，在辅助生殖技术中，肌醇和联合治疗（尽管有D-手性肌醇单药治疗）能够改善临床结局。即使需要更多的研究队列来更好地阐明这些结果，但肌醇单药治疗在预防和治疗GDM方面更有效。
